Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash from Operations (2016 - 2026)

Pharma-Bio Serv's Cash from Operations history spans 17 years, with the latest figure at 390139.0 for Q1 2026.

  • For Q1 2026, Cash from Operations rose 9.16% year-over-year to 390139.0; the TTM value through Jan 2026 reached 175539.0, up 89.81%, while the annual FY2025 figure was 214886.0, 62.08% up from the prior year.
  • Cash from Operations reached 390139.0 in Q1 2026 per PBSV's latest filing, down from 279666.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1105853.0 in Q3 2022 to a low of 700744.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 77158.29, with a median of 78425.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: surged 367.68% in 2023, then plummeted 180.18% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 260091.0 in 2022, then rose by 18.59% to 308436.0 in 2023, then crashed by 74.57% to 78425.0 in 2024, then soared by 256.6% to 279666.0 in 2025, then tumbled by 239.5% to 390139.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Cash from Operations are 390139.0 (Q1 2026), 279666.0 (Q4 2025), and 236524.0 (Q3 2025).